Clinical trial NCT00502528: Endothelin Receptor Blockade in Acute ST-elevation Myocardial Infarction
Official title: Endothelin Receptor Blockade in Acute ST-elevation Myocardial Infarction
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: ST-Elevation Myocardial Infarction
Keywords: Infarction
Endothelin
Perfusion
Lead sponsor: Medical University of Vienna
Sponsor class: OTHER
First posted: 2007-07-17
Enrollment: 57
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Background and Objective: Acute coronary syndrome is characterized by compromised blood flow at the epicardial and microvascular levels. The aim of the present study is to investigate the effect of ET-receptor blockade by BQ-123 on myocardial perfusion and infarct size as an adjunct to PCI-reperfusion therapy in patients with STEMI.

Patients are randomized to receive periinterventional intravenous BQ-123 or placebo.

Detailed description: Background and Objective: Acute coronary syndrome is characterized by compromised blood flow at the epicardial and microvascular levels. We have previously shown that thrombectomy in ST-elevation myocardial infarction (STEMI) accelerates ST-segment resolution, possibly by preventing distal embolization. Therefore, we analyzed the vasoconstrictor concentration of acute coronary thrombi, and found high concentrations of endothelin (ET) which correlated with the magnitude of ST-segment resolution within one hour of percutaneous coronary intervention (PCI). Furthermore, ET-receptor blockade by tezosentan significantly repressed vasoconstriction in an in-vitro model using porcine coronary artery rings incubated with coronary thrombus homogenates extracted from STEMI patients.

The aim of the present study is to investigate the effect of ET-receptor blockade by BQ-123 on myocardial perfusion and infarct size as an adjunct to PCI-reperfusion therapy in patients with STEMI.

Methods: Fifty eligible patients will be randomized to receive periinterventional intravenous BQ-123 or placebo. The primary endpoint of the study will be microvascular function evaluated by cardiac magnetic resonance tomography.

Eligibility criteria: Inclusion Criteria:

* STEMI patients (defined as: Evidence of ischemic chest pain for \>30 minutes within \<12 hours and new ST-segment elevation for ≥2 mm in two or more contiguous electrocardiographic leads or in case of a true posterior infarction reciprocal ST-segment depressions in in V1 and V2 \>1mm and/or elevated serum creatine phosphokinase or twofold elevation of troponin-T), aged 18 years and above, who undergo primary percutaneous revascularization (PCI) and have confirmed initial TIMI 0 or 1 in the infarct related coronary artery.

Exclusion Criteria:

* Significant liver disease
* Thrombolytic therapy
* History of prior myocardial infarction
* Current atrial fibrillation
* History of congestive heart failure
* History of migraine headache
* Significant valvular heart disease, primary myocardial disease
* Cardiogenic shock (sRR \<90mmHg or need for inotropic support)
* Child-bearing potential
* Inability to read, understand and sign the informed consent
* Life expectancy \<3y
* Prior organ transplantation
* Medication with konazoles, ritonavir, rifampicin and sulfonyl-urea derivatives
* Participation in another clinical study
* Metal implants contraindicating CMR

Primary outcomes:
measure: Myocardial perfusion determined by CMR
timeFrame: 3 days
Secondary outcomes:
measure: Final infarct size determined by CMR
timeFrame: 3 days
measure: Left ventricular function determined by CMR
timeFrame: 3 days/ 6 months (6-months Remodeling-substudy)
measure: Plasma NT-BNP
timeFrame: 30 days/ 6 months (6-months substudy)
measure: Enzymatic infarct size (CK levels)
timeFrame: 3 days
measure: ECG ST-segment resolution
timeFrame: 1 hour
measure: Markers of inflammation
timeFrame: 24 hours/ 30 days
measure: Major adverse cardiac events (MACE) (cardiovascular death, re-hospitalization for unstable angina and AMI, hospitalization for worsening heart failure)
timeFrame: 30 days
measure: Liver function
timeFrame: 24hours/ 3 days/ 30 days
measure: Event free survival
timeFrame: 6 months (6-months substudy)
measure: Holter ECG
timeFrame: 3 days / 30 days (EP-substudy)
Other outcomes:
Locations:
city: Vienna
country: Austria
facility: Medical University of Vienna
state: Vienna-Austria
Study officials:
affiliation: Medical University of Vienna
name: Irene M Lang, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Adlbrecht C, Andreas M, Redwan B, Distelmaier K, Mascherbauer J, Kaider A, Wolzt M, Tilea IA, Neunteufl T, Delle-Karth G, Maurer G, Lang IM. Systemic endothelin receptor blockade in ST-segment elevation acute coronary syndrome protects the microvasculature: a randomised pilot study. EuroIntervention. 2012 Apr;7(12):1386-95. doi: 10.4244/EIJV7I12A218.